| 名称 | Bis(maltolato)oxovanadium(IV) |
| 描述 | Bis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive, and orally active pan-PTP (protein tyrosine phosphatases) inhibitor with insulin-mimicking effects and anti-diabetic properties. BMOV is a potent insulin sensitizer and has been shown to improve cardiac dysfunctions in diabetic models. BMOV inhibits HCPTPA, PTP1B, HPTPβ, and SHP2 with IC50s of 126 nM, 109 nM, 26 nM, and 201 nM, respectively [1][2]. |
| 动物实验 | BMOV (0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; Male C57BL/6J mice) treatment ameliorates the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance. |
| 体外活性 | BMOV treatment enhances the phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt. BMOV treatment also resultes in an increased glucose uptake in C2C12 cells[1]. |
| 体内活性 | BMOV (0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; Male C57BL/6J mice) treatment ameliorates the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance. |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 13 mg/mL (40.99 mM), Sonication is recommended.
|
| 关键字 | type-2 | Phosphatase | inhibit | SHP2 | Inhibitor | phenotype | metabolic | Bis(maltolato)oxovanadium | SHP-1 | HCPTPA | uptake | glucose | HPTPβ | insulin | PTP | PTP1B | diabetes | Bis(maltolato)oxovanadium(IV) |
| 相关产品 | β-Glycerophosphate disodium salt pentahydrate | Tartaric acid disodium dihydrate | Cyclosporine | Stearic acid |
| 相关库 | 经典已知活性库 | ReFRAME 相关化合物库 | 抑制剂库 | NO PAINS 化合物库 | 口服活性化合物库 | 代谢化合物库 | 已知活性化合物库 | 磷酸酶抑制剂化合物库 |
United States
